-
公开(公告)号:US20140378299A1
公开(公告)日:2014-12-25
申请号:US14345739
申请日:2012-08-19
CPC分类号: B01J21/063 , B01J23/42 , B01J23/52 , B01J35/0013 , B01J35/002 , B01J35/006 , B01J35/06 , B01J35/1014 , B01J35/1019 , B82Y30/00 , B82Y40/00 , C01B3/16 , C01B3/583 , C01B15/029 , C01B2203/044 , C01B2203/047 , C01G23/047 , C01P2002/72 , C01P2002/85 , C01P2004/04 , C01P2004/16 , C01P2006/12 , C07B33/00 , C10K3/04 , Y02P20/52
摘要: This invention relates to a titanium dioxide catalyst particle, the catalyst particle comprising ruffle nanorods having metal nanoparticles deposited at or near the free ends of the nanorods, which is suitable to catalyse reactions after exposure to temperatures above 550 deg C. The invention also provides for the use of a catalyst particle in catalysing reactions and a method of catalysing reactions, the catalyst particle being suitable to catalyse reactions after exposure to temperatures above 550 deg C.
摘要翻译: 本发明涉及一种二氧化钛催化剂颗粒,该催化剂颗粒包含在纳米棒自由端处或附近沉积金属纳米颗粒的褶皱纳米棒,其适于在暴露于高于550℃的温度下催化反应。本发明还提供了 在催化反应中使用催化剂颗粒和催化反应的方法,催化剂颗粒适于在暴露于高于550℃的温度下催化反应。
-
公开(公告)号:US20140350080A1
公开(公告)日:2014-11-27
申请号:US14354180
申请日:2012-10-26
发明人: Patrick Arbuthnot , Justin Hean , Abdullah Ely , Musa Marimani , Jolanta Brzezinska , Jennifer D'Onofrio , Maximilian C.R. Buff , Joachim W. Engels , Stefan Bernhardt
IPC分类号: C12N15/113
CPC分类号: C12N15/1131 , A61K31/713 , C12N15/113 , C12N2310/321 , C12N2310/3527 , C12N2320/30
摘要: This invention relates to modified short interfering RNA (siRNA) nucleic acid molecules, particularly siRNA's which have been modified by the addition of a 2-0-guanidinopropyl (GP) modified nucleoside. In particular the invention relates to modified siRNAs which are capable of silencing target sequences, methods of treating and preventing infection by using the siRNAs, medicaments containing the siRNAs and use of the siRNAs.
摘要翻译: 本发明涉及经修饰的短干扰RNA(siRNA)核酸分子,特别是通过加入2-0-胍基丙基(GP)修饰的核苷而被修饰的siRNA。 特别地,本发明涉及能够沉默靶序列的修饰的siRNA,通过使用siRNAs治疗和预防感染的方法,含siRNA的药物和siRNA的用途。
-
公开(公告)号:US11713491B2
公开(公告)日:2023-08-01
申请号:US17996919
申请日:2021-04-23
IPC分类号: C12N15/09 , C12Q1/68 , C12Q1/70 , C12Q1/00 , C12Q1/6806
CPC分类号: C12Q1/70 , C12Q1/6806 , C12Q2522/101 , C12Q2525/143 , C12Q2545/113
摘要: Provided herein is a nucleotide cassette comprising an inducible promoter, a nucleotide sequence that corresponds to at least one single stranded RNA diagnostic target, a nucleotide sequence that encodes artemin, a molecular switch and a nucleotide sequence that encodes a DNAse enzyme and is under control of the molecular switch, wherein the single stranded RNA diagnostic target is a sequence detected by a molecular diagnostic assay. In some embodiments the nucleotide cassette can be used to obtain an RNA expression product. Also provided are vectors and cells comprising the nucleotide cassette or the RNA expression product thereof. The nucleotide cassette can further be used to obtain a diagnostic control composition comprising a non-pathogenic recombinant bacterium having a modified genetic content comprising the nucleotide cassette and to methods of producing such recombinant bacteria.
-
公开(公告)号:US20230127238A1
公开(公告)日:2023-04-27
申请号:US17996919
申请日:2021-04-23
IPC分类号: C12Q1/70 , C12Q1/6806
摘要: Provided herein is a nucleotide cassette comprising an inducible promoter, a nucleotide sequence that corresponds to at least one single stranded RNA diagnostic target, a nucleotide sequence that encodes artemin, a molecular switch and a nucleotide sequence that encodes a DNAse enzyme and is under control of the molecular switch, wherein the single stranded RNA diagnostic target is a sequence detected by a molecular diagnostic assay. In some embodiments the nucleotide cassette can be used to obtain an RNA expression product. Also provided are vectors and cells comprising the nucleotide cassette or the RNA expression product thereof. The nucleotide cassette can further be used to obtain a diagnostic control composition comprising a non-pathogenic recombinant bacterium having a modified genetic content comprising the nucleotide cassette and to methods of producing such recombinant bacteria.
-
25.
公开(公告)号:US20210169974A1
公开(公告)日:2021-06-10
申请号:US17177614
申请日:2021-02-17
IPC分类号: A61K38/17 , C12N15/113 , A61P17/06 , A61P21/00 , A61P9/10 , A61P39/00 , A61P3/10 , A61P35/04 , A61P19/10 , A61K39/395 , C07K14/705 , C07K16/28
摘要: The invention relates to compounds for use in the treatment of telomere related diseases and/or telomere related medical conditions, particularly wherein said telomere related diseases and/or telomere related medical conditions are cancer and cellular ageing. Particularly, herein is disclosed 37 kDa/67 kDa laminin receptor precursor/high affinity laminin receptor (LRP/LR) and/or a fragment thereof for use in the treatment and/or prevention of cellular ageing.
-
公开(公告)号:US20200299843A1
公开(公告)日:2020-09-24
申请号:US16652389
申请日:2018-09-25
摘要: THIS invention relates to a method of applying an antimicrobial surface coating to a substrate, and more particularly to a method of applying an antimicrobial surface coating to a polymeric substrate manufactured by way of additive manufacturing. The method includes the steps of providing a body to be coated, the body having a surface area and cold spraying an antimicrobial metal powder on at least part of the surface area of the body so as to form an antimicrobial coating on the body. The method is characterized in that the body is made from a polymeric material by way of an additive manufacturing process.
-
公开(公告)号:US20200092028A1
公开(公告)日:2020-03-19
申请号:US15750959
申请日:2016-08-05
IPC分类号: H04J14/04 , H04B10/516 , H04B10/66
摘要: The invention relates to optical communication methods and systems. In particular, the invention relates to an optical communication method and system which is configured to create a multiplexed beam from an incident beam, wherein the multiplexed beam comprises a predetermined number of spatial modes simultaneously generated and multiplexed together in a fashion that is independent of wavelength. The spatial modes have two degrees of spatial freedom. The multiplexed beam is de-multiplexed downstream from multiplexing thereof in the communication system in a simultaneous fashion independent of wavelength to yield the predetermined number of spatial mode. The modes are used in optical communication as channels or as bits in a bit (de) encoding scheme.
-
公开(公告)号:US20190112639A1
公开(公告)日:2019-04-18
申请号:US16090530
申请日:2017-03-31
CPC分类号: C12Q1/689 , C07K14/195 , C07K14/31 , C07K14/35 , C12N15/74 , C12Q2600/166 , C12Q2545/101
摘要: The present invention relates to a recombinant bacterium based on a non-pathogenic bacterium that has a modified genome containing a nucleic acid of interest from a pathogen that is detected by a molecular diagnostic assay and that mimics the diagnostic profile of the pathogen. The invention further relates to a diagnostic control composition comprising the recombinant bacterium and to methods for producing the recombinant bacterium. The recombinant bacterium is a safe, reliable quality control for the detection of pathogens such as Mycobacterium tuberculosis and Staphylococcus aureus. The invention also relates to a kit comprising either the recombinant bacterium, compositions containing the recombinant bacterium or bacteria produced according to the method of the invention.
-
公开(公告)号:US20190022281A1
公开(公告)日:2019-01-24
申请号:US15757475
申请日:2016-09-05
发明人: Viness PILLAY , Yahya Essop CHOONARA , Pradeep KUMAR , Lisa Claire DU TOIT , Poornima RAMBURRUN
CPC分类号: A61L27/48 , A61L27/16 , A61L27/20 , A61L27/52 , A61L27/54 , A61L27/56 , A61L27/58 , A61L2400/12 , A61L2430/32 , C08L33/12 , C08L5/08
摘要: This invention relates to biodegradable implants comprising a hydrogel carrier matrix having dispersed therein a multitude of particles, wherein each of the multitude of particles and/or the hydrogel carrier matrix includes an active pharmaceutical ingredient (API) for the treatment of transected peripheral nerve injuries. Each of the multitude of particles and/or the hydrogel carrier matrix includes pristine polymer particles, preferably the pristine polymer particles may be polymethylmethacrylate polymers and derivatives thereof, preferably poly(methacrylic-co-methyl methacrylate) (PMMA). The spheroidal particles may each be formed from an outer shell including a chitosan (CHT) poly(methacrylic-co-methyl methacrylate) (PMMA) polyelectrolyte complex (CHT-PMMA-PEC) and an inner core including crosslinked chitosan having dispersed therein PMMA nanoparticles.
-
30.
公开(公告)号:US20180325997A1
公开(公告)日:2018-11-15
申请号:US15773453
申请日:2016-11-07
IPC分类号: A61K38/17 , C07K14/705 , A61K39/395 , A61P17/06 , A61P19/10 , A61P21/00 , A61P3/10 , A61P35/04 , A61P39/00 , A61P9/10 , C07K16/28 , C12N15/113
CPC分类号: A61K38/177 , A61K39/395 , A61P3/10 , A61P9/10 , A61P17/06 , A61P19/10 , A61P21/00 , A61P35/04 , A61P39/00 , C07K14/70546 , C07K16/28 , C12N15/113 , C12N2310/14
摘要: The invention relates to compounds for use in the treatment of telomere related diseases and/or telomere related medical conditions, particularly wherein said telomere related diseases and/or telomere related medical conditions are cancer and cellular ageing. Particularly, herein is disclosed 37 kDa/67 kDa laminin receptor precursor/high affinity laminin receptor (LRP/LR) and/or a fragment thereof for use in the treatment and/or prevention of cellular ageing.
-
-
-
-
-
-
-
-
-